Loading…

A topochemical approach to explain morphiceptin bioactivity

A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 1993-03, Vol.36 (6), p.708-719
Main Authors: Yamazaki, Toshimasa, Ro, Seonggu, Goodman, Murray, Chung, Nga N, Schiller, Peter W
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3
cites
container_end_page 719
container_issue 6
container_start_page 708
container_title Journal of medicinal chemistry
container_volume 36
creator Yamazaki, Toshimasa
Ro, Seonggu
Goodman, Murray
Chung, Nga N
Schiller, Peter W
description A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic ring of phenylalanine, necessary for receptor recognition. For this purpose, 1H-NMR measurements and computer simulations were extensively carried out on 10 stereoisomeric analogs related to morphiceptin: Tyr-Pro-(L and D)-Phe- (L and D)-Pro-NH2; Tyr-Pro-(L and D)-(NMe)Phe-(L and D)-Pro-NH2; Tyr-(NMe)Ala-Phe-D-Pro-NH2; and Tyr-Ala-Phe-D-Pro-NH2. These analogs are structurally close to one another but display various opiate potencies from highly active to inactive. The conformation of each rotatable bond has been specifically identified by measuring accessible space for the analogs, in which the difference in composition is observed in the specific site affecting only the conformation around the target bond. The most interesting characteristic of the model is a requirement of a cis amide bond linking residues 1 and 2. The model also requires the side chains in a trans conformation (chi 1 = 180 degrees) for the Tyr and Phe residues. The distances between the three pharmacophores, d1 (Tyr N to Tyr OH), d2 (Tyr N to the center of the aromatic ring of the third residue), and d3 (Tyr OH to the center of the aromatic ring of the third residue), were found to be approximately 8, approximately 7, and approximately 11-13 A, respectively. This model should aid in pharmaceutical design of peptide and nonpeptide ligands with opioid potencies.
doi_str_mv 10.1021/jm00058a007
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75626238</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75626238</sourcerecordid><originalsourceid>FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3</originalsourceid><addsrcrecordid>eNptkMtLAzEQh4MotT5OnoUeRA-ymsfmsXgqRa1SUGw9h2mapam73TXZlfa_N6WlePAUJr9vhpkPoQuC7wim5H5RYoy5AozlAeoSTnGSKpweoi7GlCZUUHaMTkJYRIwRyjqoo5hKhaBd9NDvNVVdmbktnYGiB3XtKzDz-Nuzq7oAt-yVla_nzti6icXUxbhxP65Zn6GjHIpgz3fvKfp8epwMhsno7fll0B8lwBRrEmYUmeUqBykh47lhdCYUwUYZAJZn0xR4amhGp4YAJ6kAZmeZ5BDbKM9TYKfoejs3rvbd2tDo0gVjiwKWtmqDllxsblQRvN2CxlcheJvr2rsS_FoTrDeq9B9Vkb7cjW2npZ3t2Z2bmF_tcghRTe5haVzYY6mkQgoRsWSLudDY1T4G_6WFZJLryftYT0T2-jFmIz2M_M2WBxP0omr9Mrr7d8FfmMGMIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75626238</pqid></control><display><type>article</type><title>A topochemical approach to explain morphiceptin bioactivity</title><source>ACS CRKN Legacy Archives</source><creator>Yamazaki, Toshimasa ; Ro, Seonggu ; Goodman, Murray ; Chung, Nga N ; Schiller, Peter W</creator><creatorcontrib>Yamazaki, Toshimasa ; Ro, Seonggu ; Goodman, Murray ; Chung, Nga N ; Schiller, Peter W</creatorcontrib><description>A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic ring of phenylalanine, necessary for receptor recognition. For this purpose, 1H-NMR measurements and computer simulations were extensively carried out on 10 stereoisomeric analogs related to morphiceptin: Tyr-Pro-(L and D)-Phe- (L and D)-Pro-NH2; Tyr-Pro-(L and D)-(NMe)Phe-(L and D)-Pro-NH2; Tyr-(NMe)Ala-Phe-D-Pro-NH2; and Tyr-Ala-Phe-D-Pro-NH2. These analogs are structurally close to one another but display various opiate potencies from highly active to inactive. The conformation of each rotatable bond has been specifically identified by measuring accessible space for the analogs, in which the difference in composition is observed in the specific site affecting only the conformation around the target bond. The most interesting characteristic of the model is a requirement of a cis amide bond linking residues 1 and 2. The model also requires the side chains in a trans conformation (chi 1 = 180 degrees) for the Tyr and Phe residues. The distances between the three pharmacophores, d1 (Tyr N to Tyr OH), d2 (Tyr N to the center of the aromatic ring of the third residue), and d3 (Tyr OH to the center of the aromatic ring of the third residue), were found to be approximately 8, approximately 7, and approximately 11-13 A, respectively. This model should aid in pharmaceutical design of peptide and nonpeptide ligands with opioid potencies.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm00058a007</identifier><identifier>PMID: 8384662</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Analgesics - chemical synthesis ; Analgesics - chemistry ; Analgesics - pharmacology ; Animals ; Biological and medical sciences ; Computer Simulation ; Endorphins - chemical synthesis ; Endorphins - chemistry ; Endorphins - pharmacology ; Guinea Pigs ; Male ; Medical sciences ; Mice ; Models, Chemical ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Receptors, Opioid - drug effects ; Stereoisomerism ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 1993-03, Vol.36 (6), p.708-719</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm00058a007$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm00058a007$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,778,782,27047,27907,27908,56749,56799</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4726766$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8384662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamazaki, Toshimasa</creatorcontrib><creatorcontrib>Ro, Seonggu</creatorcontrib><creatorcontrib>Goodman, Murray</creatorcontrib><creatorcontrib>Chung, Nga N</creatorcontrib><creatorcontrib>Schiller, Peter W</creatorcontrib><title>A topochemical approach to explain morphiceptin bioactivity</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic ring of phenylalanine, necessary for receptor recognition. For this purpose, 1H-NMR measurements and computer simulations were extensively carried out on 10 stereoisomeric analogs related to morphiceptin: Tyr-Pro-(L and D)-Phe- (L and D)-Pro-NH2; Tyr-Pro-(L and D)-(NMe)Phe-(L and D)-Pro-NH2; Tyr-(NMe)Ala-Phe-D-Pro-NH2; and Tyr-Ala-Phe-D-Pro-NH2. These analogs are structurally close to one another but display various opiate potencies from highly active to inactive. The conformation of each rotatable bond has been specifically identified by measuring accessible space for the analogs, in which the difference in composition is observed in the specific site affecting only the conformation around the target bond. The most interesting characteristic of the model is a requirement of a cis amide bond linking residues 1 and 2. The model also requires the side chains in a trans conformation (chi 1 = 180 degrees) for the Tyr and Phe residues. The distances between the three pharmacophores, d1 (Tyr N to Tyr OH), d2 (Tyr N to the center of the aromatic ring of the third residue), and d3 (Tyr OH to the center of the aromatic ring of the third residue), were found to be approximately 8, approximately 7, and approximately 11-13 A, respectively. This model should aid in pharmaceutical design of peptide and nonpeptide ligands with opioid potencies.</description><subject>Analgesics - chemical synthesis</subject><subject>Analgesics - chemistry</subject><subject>Analgesics - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Computer Simulation</subject><subject>Endorphins - chemical synthesis</subject><subject>Endorphins - chemistry</subject><subject>Endorphins - pharmacology</subject><subject>Guinea Pigs</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Models, Chemical</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Opioid - drug effects</subject><subject>Stereoisomerism</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><recordid>eNptkMtLAzEQh4MotT5OnoUeRA-ymsfmsXgqRa1SUGw9h2mapam73TXZlfa_N6WlePAUJr9vhpkPoQuC7wim5H5RYoy5AozlAeoSTnGSKpweoi7GlCZUUHaMTkJYRIwRyjqoo5hKhaBd9NDvNVVdmbktnYGiB3XtKzDz-Nuzq7oAt-yVla_nzti6icXUxbhxP65Zn6GjHIpgz3fvKfp8epwMhsno7fll0B8lwBRrEmYUmeUqBykh47lhdCYUwUYZAJZn0xR4amhGp4YAJ6kAZmeZ5BDbKM9TYKfoejs3rvbd2tDo0gVjiwKWtmqDllxsblQRvN2CxlcheJvr2rsS_FoTrDeq9B9Vkb7cjW2npZ3t2Z2bmF_tcghRTe5haVzYY6mkQgoRsWSLudDY1T4G_6WFZJLryftYT0T2-jFmIz2M_M2WBxP0omr9Mrr7d8FfmMGMIw</recordid><startdate>19930319</startdate><enddate>19930319</enddate><creator>Yamazaki, Toshimasa</creator><creator>Ro, Seonggu</creator><creator>Goodman, Murray</creator><creator>Chung, Nga N</creator><creator>Schiller, Peter W</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930319</creationdate><title>A topochemical approach to explain morphiceptin bioactivity</title><author>Yamazaki, Toshimasa ; Ro, Seonggu ; Goodman, Murray ; Chung, Nga N ; Schiller, Peter W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Analgesics - chemical synthesis</topic><topic>Analgesics - chemistry</topic><topic>Analgesics - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Computer Simulation</topic><topic>Endorphins - chemical synthesis</topic><topic>Endorphins - chemistry</topic><topic>Endorphins - pharmacology</topic><topic>Guinea Pigs</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Models, Chemical</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Opioid - drug effects</topic><topic>Stereoisomerism</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamazaki, Toshimasa</creatorcontrib><creatorcontrib>Ro, Seonggu</creatorcontrib><creatorcontrib>Goodman, Murray</creatorcontrib><creatorcontrib>Chung, Nga N</creatorcontrib><creatorcontrib>Schiller, Peter W</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamazaki, Toshimasa</au><au>Ro, Seonggu</au><au>Goodman, Murray</au><au>Chung, Nga N</au><au>Schiller, Peter W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A topochemical approach to explain morphiceptin bioactivity</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1993-03-19</date><risdate>1993</risdate><volume>36</volume><issue>6</issue><spage>708</spage><epage>719</epage><pages>708-719</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic ring of phenylalanine, necessary for receptor recognition. For this purpose, 1H-NMR measurements and computer simulations were extensively carried out on 10 stereoisomeric analogs related to morphiceptin: Tyr-Pro-(L and D)-Phe- (L and D)-Pro-NH2; Tyr-Pro-(L and D)-(NMe)Phe-(L and D)-Pro-NH2; Tyr-(NMe)Ala-Phe-D-Pro-NH2; and Tyr-Ala-Phe-D-Pro-NH2. These analogs are structurally close to one another but display various opiate potencies from highly active to inactive. The conformation of each rotatable bond has been specifically identified by measuring accessible space for the analogs, in which the difference in composition is observed in the specific site affecting only the conformation around the target bond. The most interesting characteristic of the model is a requirement of a cis amide bond linking residues 1 and 2. The model also requires the side chains in a trans conformation (chi 1 = 180 degrees) for the Tyr and Phe residues. The distances between the three pharmacophores, d1 (Tyr N to Tyr OH), d2 (Tyr N to the center of the aromatic ring of the third residue), and d3 (Tyr OH to the center of the aromatic ring of the third residue), were found to be approximately 8, approximately 7, and approximately 11-13 A, respectively. This model should aid in pharmaceutical design of peptide and nonpeptide ligands with opioid potencies.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>8384662</pmid><doi>10.1021/jm00058a007</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 1993-03, Vol.36 (6), p.708-719
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_75626238
source ACS CRKN Legacy Archives
subjects Analgesics - chemical synthesis
Analgesics - chemistry
Analgesics - pharmacology
Animals
Biological and medical sciences
Computer Simulation
Endorphins - chemical synthesis
Endorphins - chemistry
Endorphins - pharmacology
Guinea Pigs
Male
Medical sciences
Mice
Models, Chemical
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems
Pharmacology. Drug treatments
Receptors, Opioid - drug effects
Stereoisomerism
Structure-Activity Relationship
title A topochemical approach to explain morphiceptin bioactivity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T01%3A06%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20topochemical%20approach%20to%20explain%20morphiceptin%20bioactivity&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Yamazaki,%20Toshimasa&rft.date=1993-03-19&rft.volume=36&rft.issue=6&rft.spage=708&rft.epage=719&rft.pages=708-719&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm00058a007&rft_dat=%3Cproquest_cross%3E75626238%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=75626238&rft_id=info:pmid/8384662&rfr_iscdi=true